(1S,2R)-2-methyl-1-phenylbutan-1-ol | 16725-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,2R)-2-methyl-1-phenylbutan-1-ol
• CAS: 16725-79-4
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: XYYQWQIEEXLXDX-KOLCDFICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (-)-(R)-1-phenyl-2-methyl-butane-1-one 在 三(五氟苯基)硼烷 、 三正丁基氢锡 作用下， 生成 (1R,2R)-2-methyl-1-phenylbutan-1-ol 、 (1S,2R)-2-methyl-1-phenylbutan-1-ol
  参考文献：
  名称：

  Hypercoordination of Boron and Aluminum:  Synthetic Utility as Chelating Lewis Acids

  摘要：

  DOI：

  10.1021/ja9736828

文献信息

• Prevention of Illicit Manufacutre of Methamphetamine from Pseudoephedrine Using Food Flavor Excipients
  申请人：Satara Pharmaceuticals, LLC

  公开号：US20160089439A1

  公开（公告）日：2016-03-31

  The invention relates generally to ephedrine or pseudoephedrine compositions containing biocompatible organoleptic (food flavoring) excipients that would prevent the illicit manufacture of methamphetamine from ephedrine or pseudoephedrine.

  该发明通常涉及含有生物相容性感官（食品调味）赋形剂的麻黄碱或伪麻黄碱组合物，可防止从麻黄碱或伪麻黄碱制备冰毒。
• Enantioselective synthesis of α-phenyl- and α-(dimethylphenylsilyl)alkylboronic esters by ligand mediated stereoinductive reagent-controlled homologation using configurationally labile carbenoids
  作者：Adam L. Barsamian、Zhenhua Wu、Paul R. Blakemore

  DOI：10.1039/c5ob00159e

  日期：——

  with a combination of O-(α-lithiobenzyl)-N,N-diisopropylcarbamate and ligand 3,3-bis[(4S)-4,5-dihydro-4-isopropyloxazol-2-yl] pentane in toluene solvent (−78 °C to rt) with MgBr2·OEt2 additive. Enantioenriched α-(dimethylsilylphenylsilyl)alkylboronates were obtained in 35–69% yield and 9–57% ee by reaction of B-alkyl pinacol boronates with a combination of lithio(dimethylphenylsilyl)methyl 2,4,6-triisopropylbenzoate

  在存在规模的双恶唑啉配体的存在下，通过构型不稳定的外消旋锂类胡萝卜素的作用，研究了硼酸酯的扩链，以对映异构地合成两种标题产物。最初的α-苯基烷基硼酸酯的氧化后处理（NaOOH）产生的对映体富集的2°甲醇，通过B-烷基和B-芳基新戊二醇硼酸酯与以下物质的组合反应，收率35-83％，ee达到70-96％。ø - （α-lithiobenzyl） - ñ，ñ -diisopropylcarbamate和配体3,3-双[（4-小号）-4,5-二氢-4- isopropyloxazol -2-基]戊烷在甲苯溶剂中（-78℃至rt）与MgBr 2 ·OEt 2添加剂。通过使B-烷基频哪醇硼酸酯与硫代（二甲基苯基甲硅烷基）甲基2,4,6-三异丙基苯甲酸酯和配体2,2结合反应，可得到对映体富集的α-（二甲基甲硅烷基苯基甲硅烷基）烷基硼酸酯，产率为35-69％，ee为9-57％-双[（4 S）-4,5-二氢
• DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF
  申请人：Rogers Robin D.

  公开号：US20120046244A1

  公开（公告）日：2012-02-23

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.

  本文揭示了包括活性药物、生物和营养化合物的离子液体组成，以及使用方法。进一步揭示了液态离子对或其溶液的物质组成和使用方法；包括“溶剂化”的离子液体组成，例如“水化”的离子液体组成及其用途。
• Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV
  申请人：Ormerod Dominic John

  公开号：US20130005976A1

  公开（公告）日：2013-01-03

  A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(−)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(−)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(−)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(−)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(−)-ephedrine from the precipitated salt obtained in step (b).

  一种制备[(1R,2R)-4-氧代-1,2-环戊烷二羧酸II]的方法，通过拆分混合物中的4-氧代-1,2-环戊烷二羧酸(V)得到，该方法包括：(a)将4-氧代-1,2-环戊烷二羧酸(V)与金雀碱或(1R,2S)-(-)-麻黄碱反应，从而制备出(V)的双金雀碱或双(1R,2S)-(-)-麻黄碱盐，(b)有选择地沉淀(1R,2R)-4-氧代-1,2-环戊烷二羧酸II的双金雀碱或双(1R,2S)-(-)-麻黄碱盐，而双金雀碱或双(1R,2S)-(-)-麻黄碱盐的[(1S,2S)-4-氧代-1,2-环戊烷二羧酸]保持在溶液中；(c)通过从步骤(b)中沉淀的盐中去除金雀碱或(1R,2S)-(-)-麻黄碱来释放酸II。
• CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE
  申请人：Cashman John R.

  公开号：US20110236931A1

  公开（公告）日：2011-09-29

  Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.